巴利昔单抗在心脏移植免疫诱导治疗中的应用  

Application of basiliximab for immune induction therapy in heart transplantation

作　　者：侯杰[1] Hou Jie(TEDA International Cardiovascular Hospital,Tianjin 300457)

机构地区：[1]泰达国际心血管病医院,天津300457

出　　处：《天津药学》2020年第3期59-63,共5页Tianjin Pharmacy

摘　　要：白细胞介素-2(IL-2)受体拮抗剂-巴利昔单抗应用于心脏移植免疫诱导治疗,可以显著减少心脏移植术后早期急性排斥反应的发生,且未显著增加移植后感染发生率,同时可延迟或减少钙调磷酸酶抑制剂的应用,有利于保护肾功能、促进移植物功能恢复。本文总结了巴利昔单抗的作用机制、药代动力学和临床应用,以及比较巴利昔单抗与抗胸腺细胞球蛋白在心脏移植免疫诱导治疗中的应用,为心脏移植受者免疫抑制剂的合理使用提供参考。The application of interleukin-2 receptor antagonist basiliximab to immune induction therapy for heart transplantation can significantly reduce the occurrence of early acute rejection after heart transplantation without increasing postoperative infection.At the same time,it can delay or reduce the use of calcineurin inhibitors,which is beneficial to protect renal function and promote the recovery of graft function.In this paper,we summarized the mechanism of action,pharmacokinetics and clinical application of basiliximab,and compared the application of basiliximab and anti-thymocyte globulin in the immune induction therapy of heart transplantation,so as to provide reference for the rational use of immunosuppressants for heart transplantation recipients.

关 键 词：巴利昔单抗 心脏移植 诱导治疗 急性排斥反应 

分 类 号：R979.5[医药卫生—药品]